Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. NAMUSCLA
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

NAMUSCLA

Medicine - Posted on Mar 29 2021
Active substance (DCI)
  • mexilétine
history (2)
  • 3/24/21

    NAMUSCLA (mexilétine)

    NAMUSCLA est indiqué dans le traitement symptomatique des myotonies dystrophiques chez l’adulte; ...
    icône flèche
  • 12/11/19

    NAMUSCLA (mexilétine)

    Key points Favourable opinion for reimbursement in the symptomatic treatment of myotonia in adult patients with non-dystroph...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • C01BB
Manufacturer
LUPIN EUROPE GmbH
Presentation

NAMUSCLA 167 mg, gélule
B/30 (CIP : 34009 301 721 2 4)
B/50 (CIP : 34009 301 721 3 1)
B/100 (CIP : 34009 301 721 4 8)
B/200 (CIP : 34009 550 625 8 5)

All our publications
    Congenital, genetic and rare diseases Drug therapy Muscular diseases Neuromuscular diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
hj6HQHW2YWx9MWPd